Recent News for RYTM - Rhythm Pharmaceuticals, Inc.

Date Title
Mar 8 Rhythm Pharmaceuticals misses by $0.16
Mar 8 Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results
Mar 4 Rhythm Pharmaceuticals to Present at Cowen & Co. 39th Annual Health Care Conference
Feb 7 Recent Analysis Shows Alexion Pharmaceuticals, Plug Power, Rayonier Advanced Materials, SunCoke Energy, Rhythm Pharmaceuticals, and Armstrong Flooring Market Influences — Renewed Outlook, Key Drivers of Growth
Feb 1 Rhythm Pharmaceuticals: Opportunity To Take Position Ahead Of Pivotal Data
Jan 25 A Look At The Fair Value Of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)
Jan 14 Rhythm Pharma: Investible Based On Upcoming Trial Data
Jan 4 Rhythm Pharma up 6% ahead of corporate update at JPM19
Jan 4 Rhythm Pharmaceuticals to Outline Expected 2019 Milestones and Review Updated Clinical Data in Bardet-Biedl Syndrome at 37th Annual J.P. Morgan Healthcare Conference
Dec 13 Rhythm Pharmaceuticals enrolls first patient in phase 3 trial evaluating setmelanotide in BBS and Alström Syndrome
Dec 13 Rhythm Pharmaceuticals Announces First Patient Enrolled in Pivotal Phase 3 Clinical Trial Evaluating Setmelanotide in Bardet-Biedl and Alström Syndromes
Dec 6 Rhythm Pharmaceuticals to Host Key Opinion Leader Symposium on MC4R Pathway and Patient Experience with Rare Genetic Disorders of Obesity, Including Bardet-Biedl Syndrome
Nov 15 Rhythm Pharmaceuticals Announces Presentation of Updated Clinical Data from Phase 2 Basket Studies Evaluating Setmelanotide in Alström Syndrome at ObesityWeek 2018
Nov 9 Rhythm Pharma files for $100M mixed shelf offering
Nov 9 Rhythm Pharmaceuticals misses by $0.09
Nov 9 Rhythm Pharmaceuticals Reports Third Quarter 2018 Financial Results
Nov 7 Rhythm Pharmaceuticals to Present at Stifel 2018 Healthcare Conference
Oct 17 Report: Exploring Fundamental Drivers Behind CURO Group, BiondVax Pharmaceuticals, AMAG Pharmaceuticals, AcelRx Pharmaceuticals, Ballard Power, and Rhythm Pharmaceuticals — New Horizons, Emerging Trends, and Upcoming Developments
Oct 15 Rhythm Pharmaceuticals appoints Murray W. Stewart as Chief Medical Officer
Oct 15 Rhythm Pharmaceuticals Appoints Murray W. Stewart, M.D., as Chief Medical Officer
Sep 28 Rhythm Pharmaceuticals Announces Launch of TEMPO Registry for Rare Genetic Disorders of Obesity
Sep 28 Rhythm Pharmaceuticals Announces Presentation of Updated Clinical Data from Phase 2 Basket Studies Evaluating Setmelanotide in Bardet-Biedl Syndrome and Alström Syndrome at 57th Annual ESPE Meeting
Sep 25 Rhythm Pharmaceuticals to Present at Ladenburg Thalmann 2018 Healthcare Conference

Back to the Main RYTM Page...